187 related articles for article (PubMed ID: 9599225)
1. Design and synthesis of cyclic inhibitors of matrix metalloproteinases and TNF-alpha production.
Xue CB; He X; Roderick J; DeGrado WF; Cherney RJ; Hardman KD; Nelson DJ; Copeland RA; Jaffee BD; Decicco CP
J Med Chem; 1998 May; 41(11):1745-8. PubMed ID: 9599225
[No Abstract] [Full Text] [Related]
2. Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.
Pikul S; McDow Dunham KL; Almstead NG; De B; Natchus MG; Anastasio MV; McPhail SJ; Snider CE; Taiwo YO; Chen L; Dunaway CM; Gu F; Mieling GE
J Med Chem; 1999 Jan; 42(1):87-94. PubMed ID: 9888835
[TBL] [Abstract][Full Text] [Related]
3. Dual inhibition of phosphodiesterase 4 and matrix metalloproteinases by an (arylsulfonyl)hydroxamic acid template.
Groneberg RD; Burns CJ; Morrissette MM; Ullrich JW; Morris RL; Darnbrough S; Djuric SW; Condon SM; McGeehan GM; Labaudiniere R; Neuenschwander K; Scotese AC; Kline JA
J Med Chem; 1999 Feb; 42(4):541-4. PubMed ID: 10052961
[No Abstract] [Full Text] [Related]
4. Discovery of potent, achiral matrix metalloproteinase inhibitors.
Pikul S; McDow Dunham KL; Almstead NG; De B; Natchus MG; Anastasio MV; McPhail SJ; Snider CE; Taiwo YO; Rydel T; Dunaway CM; Gu F; Mieling GE
J Med Chem; 1998 Sep; 41(19):3568-71. PubMed ID: 9733482
[No Abstract] [Full Text] [Related]
5. Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.
Duan JJ; Chen L; Wasserman ZR; Lu Z; Liu RQ; Covington MB; Qian M; Hardman KD; Magolda RL; Newton RC; Christ DD; Wexler RR; Decicco CP
J Med Chem; 2002 Nov; 45(23):4954-7. PubMed ID: 12408705
[TBL] [Abstract][Full Text] [Related]
6. Structure-based design and synthesis of a series of hydroxamic acids with a quaternary-hydroxy group in P1 as inhibitors of matrix metalloproteinases.
Jacobson IC; Reddy PG; Wasserman ZR; Hardman KD; Covington MB; Arner EC; Copeland RA; Decicco CP; Magolda RL
Bioorg Med Chem Lett; 1998 Apr; 8(7):837-42. PubMed ID: 9871551
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and molecular modeling study of iminodiacetyl monohydroxamic acid derivatives as MMP inhibitors.
Santos MA; Marques SM; Tuccinardi T; Carelli P; Panelli L; Rossello A
Bioorg Med Chem; 2006 Nov; 14(22):7539-50. PubMed ID: 16875829
[TBL] [Abstract][Full Text] [Related]
8. A novel series of highly selective inhibitors of MMP-3.
Whitlock GA; Dack KN; Dickinson RP; Lewis ML
Bioorg Med Chem Lett; 2007 Dec; 17(24):6750-3. PubMed ID: 18029177
[TBL] [Abstract][Full Text] [Related]
9. Macrocyclic amino carboxylates as selective MMP-8 inhibitors.
Cherney RJ; Wang L; Meyer DT; Xue CB; Wasserman ZR; Hardman KD; Welch PK; Covington MB; Copeland RA; Arner EC; DeGrado WF; Decicco CP
J Med Chem; 1998 May; 41(11):1749-51. PubMed ID: 9599226
[No Abstract] [Full Text] [Related]
10. 3-Hydroxy-4-arylsulfonyltetrahydropyranyl-3-hydroxamic acids are novel inhibitors of MMP-13 and aggrecanase.
Noe MC; Snow SL; Wolf-Gouveia LA; Mitchell PG; Lopresti-Morrow L; Reeves LM; Yocum SA; Liras JL; Vaughn M
Bioorg Med Chem Lett; 2004 Sep; 14(18):4727-30. PubMed ID: 15324896
[TBL] [Abstract][Full Text] [Related]
11. N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets.
Hanessian S; Moitessier N; Gauchet C; Viau M
J Med Chem; 2001 Sep; 44(19):3066-73. PubMed ID: 11543675
[TBL] [Abstract][Full Text] [Related]
12. Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors.
Hanessian S; Bouzbouz S; Boudon A; Tucker GC; Peyroulan D
Bioorg Med Chem Lett; 1999 Jun; 9(12):1691-6. PubMed ID: 10397503
[TBL] [Abstract][Full Text] [Related]
13. Sultam hydroxamates as novel matrix metalloproteinase inhibitors.
Cherney RJ; Mo R; Meyer DT; Hardman KD; Liu RQ; Covington MB; Qian M; Wasserman ZR; Christ DD; Trzaskos JM; Newton RC; Decicco CP
J Med Chem; 2004 Jun; 47(12):2981-3. PubMed ID: 15163180
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of matrix metalloproteinase inhibitors guided by molecular modeling. Picking the S(1) pocket using conformationally constrained inhibitors.
Hanessian S; MacKay DB; Moitessier N
J Med Chem; 2001 Sep; 44(19):3074-82. PubMed ID: 11543676
[TBL] [Abstract][Full Text] [Related]
15. Macrocyclic hydroxamate inhibitors of matrix metalloproteinases and TNF-alpha production.
Cherney RJ; Wang L; Meyer DT; Xue CB; Arner EC; Copeland RA; Covington MB; Hardman KD; Wasserman ZR; Jaffee BD; Decicco CP
Bioorg Med Chem Lett; 1999 May; 9(9):1279-84. PubMed ID: 10340614
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of matrix metalloproteinases by peptidyl hydroxamic acids.
Odake S; Morita Y; Morikawa T; Yoshida N; Hori H; Nagai Y
Biochem Biophys Res Commun; 1994 Mar; 199(3):1442-6. PubMed ID: 8147888
[TBL] [Abstract][Full Text] [Related]
17. The synthesis of novel matrix metalloproteinase inhibitors employing the Ireland-Claisen rearrangement.
Pratt LM; Beckett RP; Bellamy CL; Corkill DJ; Cossins J; Courtney PF; Davies SJ; Davidson AH; Drummond AH; Helfrich K; Lewis CN; Mangan M; Martin FM; Miller K; Nayee P; Ricketts ML; Thomas W; Todd RS; Whittaker M
Bioorg Med Chem Lett; 1998 Jun; 8(11):1359-64. PubMed ID: 9871766
[TBL] [Abstract][Full Text] [Related]
18. New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.
Sawa M; Kiyoi T; Kurokawa K; Kumihara H; Yamamoto M; Miyasaka T; Ito Y; Hirayama R; Inoue T; Kirii Y; Nishiwaki E; Ohmoto H; Maeda Y; Ishibushi E; Inoue Y; Yoshino K; Kondo H
J Med Chem; 2002 Feb; 45(4):919-29. PubMed ID: 11831904
[TBL] [Abstract][Full Text] [Related]
19. Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release.
Xue CB; He X; Corbett RL; Roderick J; Wasserman ZR; Liu RQ; Jaffee BD; Covington MB; Qian M; Trzaskos JM; Newton RC; Magolda RL; Wexler RR; Decicco CP
J Med Chem; 2001 Oct; 44(21):3351-4. PubMed ID: 11585440
[TBL] [Abstract][Full Text] [Related]
20. New alpha-substituted succinate-based hydroxamic acids as TNFalpha convertase inhibitors.
Barlaam B; Bird TG; Lambert-Van Der Brempt C; Campbell D; Foster SJ; Maciewicz R
J Med Chem; 1999 Nov; 42(23):4890-908. PubMed ID: 10579851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
